These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 28025563)

  • 21. Capturing Peptide-GPCR Interactions and Their Dynamics.
    Kaiser A; Coin I
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33076289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mapping the putative G protein-coupled receptor (GPCR) docking site on GPCR kinase 2: insights from intact cell phosphorylation and recruitment assays.
    Beautrait A; Michalski KR; Lopez TS; Mannix KM; McDonald DJ; Cutter AR; Medina CB; Hebert AM; Francis CJ; Bouvier M; Tesmer JJ; Sterne-Marr R
    J Biol Chem; 2014 Sep; 289(36):25262-75. PubMed ID: 25049229
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function.
    Kristiansen K
    Pharmacol Ther; 2004 Jul; 103(1):21-80. PubMed ID: 15251227
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulation of GPCR Trafficking by Ubiquitin.
    Kennedy JE; Marchese A
    Prog Mol Biol Transl Sci; 2015; 132():15-38. PubMed ID: 26055053
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Open Question of How GPCRs Interact with GPCR Kinases (GRKs).
    Cato MC; Yen YC; Francis CJ; Elkins KE; Shareef A; Sterne-Marr R; Tesmer JJG
    Biomolecules; 2021 Mar; 11(3):. PubMed ID: 33802765
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural Characterization of Receptor-Receptor Interactions in the Allosteric Modulation of G Protein-Coupled Receptor (GPCR) Dimers.
    Lazim R; Suh D; Lee JW; Vu TNL; Yoon S; Choi S
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33810175
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oligomerization of GPCRs involved in endocrine regulation.
    Kleinau G; Müller A; Biebermann H
    J Mol Endocrinol; 2016 Jul; 57(1):R59-80. PubMed ID: 27151573
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted Elimination of G Proteins and Arrestins Defines Their Specific Contributions to Both Intensity and Duration of G Protein-coupled Receptor Signaling.
    Alvarez-Curto E; Inoue A; Jenkins L; Raihan SZ; Prihandoko R; Tobin AB; Milligan G
    J Biol Chem; 2016 Dec; 291(53):27147-27159. PubMed ID: 27852822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. GPCR oligomers in pharmacology and signaling.
    González-Maeso J
    Mol Brain; 2011 May; 4(1):20. PubMed ID: 21619615
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chapter Three - Ubiquitination and Protein Turnover of G-Protein-Coupled Receptor Kinases in GPCR Signaling and Cellular Regulation.
    Penela P
    Prog Mol Biol Transl Sci; 2016; 141():85-140. PubMed ID: 27378756
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Post-Translational Modifications of G Protein-Coupled Receptors Revealed by Proteomics and Structural Biology.
    Zhang B; Li S; Shui W
    Front Chem; 2022; 10():843502. PubMed ID: 35355784
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structural Mass Spectrometry Captures Residue-Resolved Comprehensive Conformational Rearrangements of a G Protein-Coupled Receptor.
    Liu H; Yan P; Zhang Z; Han H; Zhou Q; Zheng J; Zhang J; Xu F; Shui W
    J Am Chem Soc; 2024 Jul; 146(29):20045-20058. PubMed ID: 39001877
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterizing pharmacological ligands to study the long-chain fatty acid receptors GPR40/FFA1 and GPR120/FFA4.
    Milligan G; Alvarez-Curto E; Watterson KR; Ulven T; Hudson BD
    Br J Pharmacol; 2015 Jul; 172(13):3254-65. PubMed ID: 25131623
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging structural insights into biased GPCR signaling.
    Shukla AK; Singh G; Ghosh E
    Trends Biochem Sci; 2014 Dec; 39(12):594-602. PubMed ID: 25458114
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The pharmacology of TUG-891, a potent and selective agonist of the free fatty acid receptor 4 (FFA4/GPR120), demonstrates both potential opportunity and possible challenges to therapeutic agonism.
    Hudson BD; Shimpukade B; Mackenzie AE; Butcher AJ; Pediani JD; Christiansen E; Heathcote H; Tobin AB; Ulven T; Milligan G
    Mol Pharmacol; 2013 Nov; 84(5):710-25. PubMed ID: 23979972
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Agonist-selective recruitment of engineered protein probes and of GRK2 by opioid receptors in living cells.
    Stoeber M; Jullié D; Li J; Chakraborty S; Majumdar S; Lambert NA; Manglik A; von Zastrow M
    Elife; 2020 Feb; 9():. PubMed ID: 32096468
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural insights into ligand recognition and selectivity for classes A, B, and C GPCRs.
    Lee SM; Booe JM; Pioszak AA
    Eur J Pharmacol; 2015 Sep; 763(Pt B):196-205. PubMed ID: 25981303
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NMR investigation of protein-ligand interactions for G-protein coupled receptors.
    Raingeval C; Krimm I
    Future Med Chem; 2019 Jul; 11(14):1811-1825. PubMed ID: 31287732
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determination of GPCR Phosphorylation Status: Establishing a Phosphorylation Barcode.
    Prihandoko R; Bradley SJ; Tobin AB; Butcher AJ
    Curr Protoc Pharmacol; 2015 Jun; 69():2.13.1-2.13.26. PubMed ID: 26344213
    [TBL] [Abstract][Full Text] [Related]  

  • 40. GPCR desensitization: Acute and prolonged phases.
    Rajagopal S; Shenoy SK
    Cell Signal; 2018 Jan; 41():9-16. PubMed ID: 28137506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.